Anixa reports first 90-day stable disease in Phase 1 ovarian cancer CAR-T trial

Bitget2026/10/05 12:16

Anixa Biosciences reported the first case of stable disease lasting three months in its Phase 1 ovarian cancer CAR-T trial. The result has already been observed in a patient treated in the highest-dose cohort evaluated so far. No dose-limiting toxicities have been seen to date, supporting continued dose escalation and further evaluation of early efficacy signals. Several treated patients have lived more than a year since therapy, including one beyond two years, suggesting potential durability worth monitoring. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anixa Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610050815PR_NEWS_USPR_____LA62990) on October 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

Viral Altcoin Defies Market Slumber With 53% Surge, BTC Calms at $83K: Weekend Watch

Cryptopotato•2026/10/11 10:21

Global Bank Stocks Sink as Bond Losses Top $326 Billion: Is Another SVB Coming?

BeInCrypto•2026/10/11 10:06

Exclusive Report - Sources Say INWIT Investors Are Raising Funds for a Possible Privatization Deal

路透社•2026/10/11 08:51

About 700,000 BTC have flowed out of exchanges in the past year.

AiCoin•2026/10/11 07:37